Abliva's KL1333 clinical development plan for treatment of PMD receives positive feedback from US FDA

Abliva AB has received positive feedback from the US Food and Drug Administration (FDA) on its KL1333 clinical development plan for the treatment of primary mitochondrial disease (PMD) at a pre─Investigational New Drug (pre─IND) meeting.